MX350717B - Nuevos derivados biciclicos de dihidroisoquinolin-1-ona. - Google Patents
Nuevos derivados biciclicos de dihidroisoquinolin-1-ona.Info
- Publication number
- MX350717B MX350717B MX2014005833A MX2014005833A MX350717B MX 350717 B MX350717 B MX 350717B MX 2014005833 A MX2014005833 A MX 2014005833A MX 2014005833 A MX2014005833 A MX 2014005833A MX 350717 B MX350717 B MX 350717B
- Authority
- MX
- Mexico
- Prior art keywords
- dihydroisoquinoline
- derivatives
- compounds
- new bicyclic
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona nuevos compuestos que tienen la fórmula general (I) (ver Fórmula) en la que R1, R2, R3, R4, R5, R6, A1, A2, A3, A4, A5 y n tienen los significados aquí definidos, las composiciones que incluyen los compuestos y métodos para el uso de los compuestos como inhibidores de la aldosterona-sintasa (CYP11B2 o CYP11B1) para el tratamiento o la profilaxis de las enfermedades renales crónicas, la insuficiencia cardíaca congestiva, la hipertensión, el aldosteronismo primario y el síndrome de Cushing.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011083229 | 2011-11-30 | ||
| PCT/EP2012/073653 WO2013079452A1 (en) | 2011-11-30 | 2012-11-27 | New bicyclic dihydroisoquinoline-1-one derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005833A MX2014005833A (es) | 2014-06-04 |
| MX350717B true MX350717B (es) | 2017-09-14 |
Family
ID=47297189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005833A MX350717B (es) | 2011-11-30 | 2012-11-27 | Nuevos derivados biciclicos de dihidroisoquinolin-1-ona. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9133158B2 (es) |
| EP (2) | EP3587401A1 (es) |
| JP (1) | JP6382108B2 (es) |
| KR (1) | KR102089927B1 (es) |
| AR (1) | AR088989A1 (es) |
| AU (1) | AU2012344041B2 (es) |
| BR (1) | BR112014013136B1 (es) |
| CA (1) | CA2850700C (es) |
| CL (1) | CL2014001389A1 (es) |
| CO (1) | CO6920296A2 (es) |
| CR (1) | CR20140229A (es) |
| DK (1) | DK2785695T3 (es) |
| EA (1) | EA035454B1 (es) |
| ES (1) | ES2811806T3 (es) |
| HR (1) | HRP20201277T1 (es) |
| HU (1) | HUE050431T2 (es) |
| IL (1) | IL232570B (es) |
| LT (1) | LT2785695T (es) |
| MA (1) | MA35664B1 (es) |
| MX (1) | MX350717B (es) |
| MY (1) | MY178867A (es) |
| PE (1) | PE20141283A1 (es) |
| PH (1) | PH12014501179B1 (es) |
| PL (1) | PL2785695T3 (es) |
| PT (1) | PT2785695T (es) |
| RS (1) | RS60660B1 (es) |
| SG (1) | SG11201402199QA (es) |
| SI (1) | SI2785695T1 (es) |
| TW (1) | TWI583678B (es) |
| UA (1) | UA112565C2 (es) |
| WO (1) | WO2013079452A1 (es) |
| ZA (1) | ZA201402908B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CN105358534A (zh) * | 2013-04-23 | 2016-02-24 | 斯洛文尼亚莱柯制药股份有限公司 | 8-氯-1-甲基-苯并[d]吖庚因的新合成方法、新的中间体及其生产方法 |
| US9266904B2 (en) * | 2013-05-17 | 2016-02-23 | Hoffmann-La Roche Inc. | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
| EP3719019B1 (en) * | 2013-05-27 | 2022-01-19 | F. Hoffmann-La Roche AG | New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds |
| MY176401A (en) * | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
| CR20170118A (es) * | 2014-10-08 | 2017-07-10 | Hoffmann La Roche | Derivados espirodiamina como inhibidores de la aldosterona sintasa |
| US9745289B2 (en) * | 2014-10-15 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| US10759791B2 (en) | 2014-11-04 | 2020-09-01 | Northwestern University | Mammalian and bacterial nitric oxide synthase inhibitors |
| JP6707084B2 (ja) * | 2014-12-02 | 2020-06-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| JP6314196B2 (ja) * | 2015-10-22 | 2018-04-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP6545275B2 (ja) * | 2015-10-23 | 2019-07-17 | 田辺三菱製薬株式会社 | 新規含窒素芳香族複素環化合物 |
| CA3009159C (en) | 2015-12-24 | 2024-03-19 | Kyowa Hakko Kirin Co., Ltd. | .alpha.,.beta.-unsaturated amide compound |
| CA3041033A1 (en) * | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Monocyclic compounds useful as gpr120 modulators |
| JP7065081B2 (ja) | 2016-09-12 | 2022-05-11 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な二環式化合物 |
| AU2018209573B2 (en) * | 2017-01-22 | 2020-08-13 | Fujian Akeylink Biotechnology Co., Ltd. | ASK1 inhibitor and preparation method and use thereof |
| JP7221202B2 (ja) | 2017-06-23 | 2023-02-13 | 協和キリン株式会社 | α、β不飽和アミド化合物 |
| WO2019016112A1 (en) | 2017-07-17 | 2019-01-24 | AbbVie Deutschland GmbH & Co. KG | SUBSTITUTED QUINOLINE COMPOUNDS IN POSITIONS 1, 2, 3 AND 4 AS MODULATORS OF S1P |
| CN109810171B (zh) * | 2017-11-21 | 2020-12-01 | 首都医科大学 | 二氢异喹啉-3-甲酰-LARGD(aa)aa,其制备,抗静脉血栓活性和应用 |
| WO2019136025A1 (en) | 2018-01-02 | 2019-07-11 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
| KR102613340B1 (ko) * | 2018-06-26 | 2023-12-14 | 쩌지앙 빔그린 파머슈티컬스, 엘티디 | A2a 수용체 길항제로서의 트리아졸로 트리아진 유도체 |
| EP3962903A1 (en) | 2019-05-01 | 2022-03-09 | Boehringer Ingelheim International GmbH | (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| WO2023063851A1 (en) * | 2021-10-13 | 2023-04-20 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
| WO2024061371A1 (zh) * | 2022-09-23 | 2024-03-28 | 广州威诺森医药科技有限公司 | 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用 |
| WO2024102026A1 (en) * | 2022-11-10 | 2024-05-16 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4710507A (en) | 1983-12-22 | 1987-12-01 | Pfizer Inc. | Quinolone inotropic agents |
| CA2439410C (en) * | 2001-02-27 | 2011-09-06 | William D. Figg | Analogs of thalidomide as potential angiogenesis inhibitors |
| AU2007234968A1 (en) * | 2006-03-29 | 2007-10-18 | Novartis Ag | Organic compounds |
| AU2008279776B2 (en) * | 2007-07-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| KR20120023091A (ko) * | 2009-05-15 | 2012-03-12 | 노파르티스 아게 | 5-피리딘-3-일-1,3-디히드로-인돌-2-온 유도체, 및 알도스테론 신타제 및/또는 ｃｙｐ11ｂ1의 조절제로서의 그의 용도 |
| JP2013537210A (ja) * | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
-
2012
- 2012-11-27 RS RS20200979A patent/RS60660B1/sr unknown
- 2012-11-27 PE PE2014000766A patent/PE20141283A1/es active IP Right Grant
- 2012-11-27 PT PT127978179T patent/PT2785695T/pt unknown
- 2012-11-27 WO PCT/EP2012/073653 patent/WO2013079452A1/en active Application Filing
- 2012-11-27 KR KR1020147018023A patent/KR102089927B1/ko active IP Right Grant
- 2012-11-27 BR BR112014013136-8A patent/BR112014013136B1/pt active IP Right Grant
- 2012-11-27 SG SG11201402199QA patent/SG11201402199QA/en unknown
- 2012-11-27 EA EA201491018A patent/EA035454B1/ru not_active IP Right Cessation
- 2012-11-27 JP JP2014543854A patent/JP6382108B2/ja active Active
- 2012-11-27 DK DK12797817.9T patent/DK2785695T3/da active
- 2012-11-27 EP EP19187075.7A patent/EP3587401A1/en active Pending
- 2012-11-27 ES ES12797817T patent/ES2811806T3/es active Active
- 2012-11-27 MX MX2014005833A patent/MX350717B/es active IP Right Grant
- 2012-11-27 EP EP12797817.9A patent/EP2785695B1/en active Active
- 2012-11-27 HU HUE12797817A patent/HUE050431T2/hu unknown
- 2012-11-27 UA UAA201407120A patent/UA112565C2/uk unknown
- 2012-11-27 PL PL12797817T patent/PL2785695T3/pl unknown
- 2012-11-27 MY MYPI2014701399A patent/MY178867A/en unknown
- 2012-11-27 AR ARP120104439A patent/AR088989A1/es active IP Right Grant
- 2012-11-27 LT LTEP12797817.9T patent/LT2785695T/lt unknown
- 2012-11-27 SI SI201231822T patent/SI2785695T1/sl unknown
- 2012-11-27 CA CA2850700A patent/CA2850700C/en active Active
- 2012-11-27 AU AU2012344041A patent/AU2012344041B2/en not_active Ceased
- 2012-11-29 US US13/688,373 patent/US9133158B2/en active Active
- 2012-11-29 TW TW101144851A patent/TWI583678B/zh active
-
2014
- 2014-03-31 CO CO14068498A patent/CO6920296A2/es active IP Right Grant
- 2014-04-22 ZA ZA2014/02908A patent/ZA201402908B/en unknown
- 2014-05-12 IL IL232570A patent/IL232570B/en active IP Right Grant
- 2014-05-15 CR CR20140229A patent/CR20140229A/es unknown
- 2014-05-26 PH PH12014501179A patent/PH12014501179B1/en unknown
- 2014-05-27 MA MA37074A patent/MA35664B1/fr unknown
- 2014-05-27 CL CL2014001389A patent/CL2014001389A1/es unknown
-
2020
- 2020-08-13 HR HRP20201277TT patent/HRP20201277T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501179A1 (en) | New bicyclic dihydroisoquinoline-1-one derivatives | |
| PH12017500658A1 (en) | Spirodiamine derivatives as aldosterone synthase inhibitors | |
| PH12020500195A1 (en) | Pyrimidinones as factor xia inhibitors | |
| MX345763B (es) | Nuevos macrociclos como inhibidores del factor xia. | |
| MX2012008874A (es) | Macrociclos como inhibidores del factor de coagulacion (fxia). | |
| MX358376B (es) | Nuevos derivados dihidroquinolina-2-ona. | |
| EP2595482A4 (en) | ALDOSTERONSYNTHASEHEMMER | |
| EP4219465A3 (en) | Prmt5 inhibitors and uses thereof | |
| WO2011138751A3 (en) | Heterocyclic derivatives as alk inhibitors | |
| UA115136C2 (uk) | Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1 | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| MX2014001879A (es) | Aminoquinazolinas como inhibidores de quinasa. | |
| MX2014014531A (es) | Derivados de aminoquinazolina y piridopirimidina. | |
| MX2015007097A (es) | Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer. | |
| MX363551B (es) | Compuestos derivados de pirazina como inhibidores de cinasa. | |
| AU2015292632B2 (en) | Aldosterone synthase inhibitors | |
| MX369025B (es) | Inhibidores de aldosterona sintasa. | |
| MX2015010611A (es) | Nuevos derivados de dihidroquinolin-2-ona como inhibidores de la aldosterona-sintasa (citocromo p450, familia 11, subfamilia b, polipeptido 2 (cyp11b2) o citocromo p450, familia 11, subfamilia b, polipeptido 1 (cyp11b1)). | |
| WO2012154879A3 (en) | Autophagy inhibitors | |
| PH12014501979B1 (en) | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor | |
| MX2016003926A (es) | Nuevos derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa. | |
| MX2014008856A (es) | Derivados de imidazolilcetona como inhibidores de aldosterona sintasa. | |
| NZ741335A (en) | New bicyclic dihydroisoquinoline-1-one derivatives | |
| GB201016442D0 (en) | Novel acridine derivatives | |
| NZ747821A (en) | Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |